New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2012
22:29 EDTWAG, ESRXWalgreen's stock could be a "risky bet", Barron's contends
Walgreen (WAG) is still feeling the sting from when it parted ways with pharmacy-benefit giant Express Scripts (ESRX) on Jan. 1. The two were unable to come to terms on a new contract that would cover more than $5B in business. Walgreen trades at a P/E ratio well below its historical average. But with more pain possibly on the horizon now that Express Scripts has formerly completed its merger with rival Medco Health Solutions, Barron's wouldn't jump in just yet. Reference Link
News For WAG;ESRX From The Last 14 Days
Check below for free stories on WAG;ESRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
06:53 EDTWAGFood & Drug Law Institute to hold a conference
Subscribe for More Information
April 22, 2014
13:49 EDTWAGWalgreens jumps to highs after comments from JANA's Rosenstein
13:48 EDTWAGWalgreens is JANA Partners' largest position
Subscribe for More Information
07:24 EDTWAGSourceMedia to hold a forum
26th Annual Card Forum & Expo is being held in Orlando on April 22-25.
April 21, 2014
09:47 EDTESRXExpress Scripts' TriCare contract renewal removes an overhang, says UBS
UBS said Express Scripts successful renewal of the TriCare/Department of Defense PBM contract removes an overhang and should contribute 25c-30c to 2014 earnings. The firm expects shares to react positively and reiterates its Buy rating and $72 price target.
09:38 EDTESRXExpress Scripts TRICARE contract removes key overhang, says Citigroup
Citigroup believes the Express Scripts retaining the Department of Defense's TRICARE Pharmacy Program contract removes a key overhang on the stock and validates the company's business model. Citi reiterates a Buy rating on Express Scripts with a $92 price target.
April 19, 2014
18:41 EDTESRXExpress Scripts awarded 7-year TRICARE Pharmacy Program contract
Subscribe for More Information
April 13, 2014
16:41 EDTWAGWalgreens investor group urges for re-domiciling tax base to Europe, FT says
Subscribe for More Information
April 11, 2014
09:08 EDTWAGWalgreens has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO Greg Wasson on April 17 at 2 pm.
April 10, 2014
11:28 EDTWAGWalgreens management to meet with BB&T
Subscribe for More Information
11:23 EDTWAGRite Aid hits 52-week high after results, sales view top estimates
Shares of retail drugstore Rite Aid (RAD) are rallying after the company's fourth quarter results and fiscal 2015 revenue outlook topped analysts' consensus estimates. WHAT'S NEW: This morning, Rite Aid reported fourth quarter adjusted earnings per share of 10c and revenue of $6.6B, compared to expectations of 4c and $6.54B, respectively. Q4 same store sales increased 2.1%. Rite Aid forecast FY15 EPS of 31c-42c, compared to the consensus of 35c. FY15 revenue was seen at $26B-$26.5B, ahead of the consensus $25.75B. FY15 same-store sales are expected by the company to be up 2.5%-4.5%. WHAT'S NOTABLE: Rite Aid also announced it has acquired RediClinic, which currently operates 30 clinics in the greater Houston, Austin and San Antonio areas. Rite Aid CEO John Standley said, “Our recent acquisitions of Health Dialog and RediClinic, our expanded partnership with McKesson and our continued commitment to investing in our store base have positioned us to transition our strategy from turnaround to growth as we more aggressively pursue opportunities to become a growing retail healthcare company.” PRICE ACTION: In late morning trading, Rite Aid rose 71c, or about 11%, to $7.11 on more than twice its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week high of $7.39. Including today's advance, the stock is up approximately 300% over the past twelve months. OTHERS TO WATCH: Other retail drugstore operators include Walgreen Company (WAG) and CVS Caremark (CVS).
April 9, 2014
11:43 EDTESRXGilead defended by analysts after recent pullback
Subscribe for More Information
08:41 EDTESRXAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use